Increasing concentrations of serum S100B is indicative of disease progression, with a moderate increase in concentration between stages I–III melanoma patients and a dramatic increase in concentration between stages III–IV melanoma patients [10,11,12], by which time survival rates have already dropped to 10–25% [2]. Here, S100B is linked to melanoma.